MajesTEC-3 trial: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

MajesTEC-3

10 Most Promising Cancer Drugs Not Yet Approved in 2025: Solid Tumors Edition by OncoDaily

10 most promising cancer drugs 2025

Final Results of CARES-310 Study: Camrelizumab + Rivoceranib vs Sorafenib in Unresectable HCC

CARES-310

Prof. Ruben Mesa Recognized with the 2025 ASH Ernest Beutler Lecture and Prize

Ruben Mesa - OncoDaily

Alicia Zhou: The Mission-Driven Biologist Building the Future of Immunotherapy

Alicia Zhou

Oncology News, Insights, Stories by OncoDaily

OncoCalendar

Advocates Webinar: Unlocking Next-Generation Therapies

Friends of Cancer Research

11 Jun
Advocates Webinar

Unlocking Next-Generation Therapies

Friends of Cancer Research

06 May
Next-Generation Therapies

Advocates Webinar: External Control Arms in Oncology Drug Development

Friends of Cancer Research

23 Apr
Advocates Webinar

Application of External Control Arms in Oncology Drug Development

Friends of Cancer Research

07 Apr
External Control Arms

Advocates Webinar: Modernizing Oncology Endpoints

Friends of Cancer Research

19 Feb
Advocates Webinar